Plus Therapeutics announced on August 18, 2025, positive data from the ReSPECT-LM Phase 1 single dose escalation trial. The results were presented at the SNO/ASCO CNS Metastases Conference in Baltimore, MD.
The data demonstrated that treatment of leptomeningeal metastases (LM) with REYOBIQ is feasible, has a manageable safety profile, and shows a promising efficacy signal. REYOBIQ produced a clinical benefit rate of over 75% across three clinically relevant outcome measures.
RNA sequencing and circulating tumor cell reduction were consistent with tumor cell death, and no dose-limiting toxicities were observed with an overall favorable safety profile. The study included a total of 29 subjects across cohorts 1 through 6.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.